Unknown

Dataset Information

0

Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.


ABSTRACT:

Background

Despite numerous chimeric antigen receptor T-cell (CAR-T) trials conducted in China, no CAR-T has been registered in the country. Furthermore, China law and regulations restrict the export of patient material for CAR-T manufacture abroad. Relma-cel (JWCAR029), an anti-CD19 product produced with a commercial-ready process in China, was evaluated in the first prospective, single-arm, multicenter, pivotal study of CAR-T therapy conducted under Chinese IND to support an NMPA-accepted BLA submission in relapsed/refractory (r/r) LBCL (NCT04089215).

Methods

Patients were randomized to receive either 100 × 106 (low dose, n = 27) or 150 × 106 (high dose, n = 32) CAR+ T-cells as a single infusion following lymphodepleting chemotherapy (fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2 daily × 3), and then, monitored for efficacy and safety outcomes and pharmacokinetics. The primary endpoint was ORR at 3 months, as assessed by the investigators. Secondary endpoints included DOR, PFS, OS, and adverse event frequency/severity and cell expansion kinetics.

Results

As of the data cutoff on 17 June 2020, 68 patients were enrolled, and 59 were treated. Among the 58 efficacy-evaluable patients, the primary endpoint of 3 month ORR was 60.3% (95% CI, 46.6-73.0), excluding the null hypothesis rate of 20%. Any grade and severe grade CRS occurred in 47.5% and 5.1%, respectively, and any grade and severe grade neurotoxicity events occurred in 20.3% and 5.1%.

Conclusions

Relma-cel met the primary endpoint analysis and demonstrated a high rate of durable responses and low rate of CAR-T-associated toxicities in patients with r/r LBCL in a multicenter trial supporting regulatory submission in China.

SUBMITTER: Ying Z 

PROVIDER: S-EPMC7897944 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.

Ying Zhitao Z   Yang Haiyan H   Guo Ye Y   Li Wenyu W   Zou Dehui D   Zhou Daobin D   Wang Zhao Z   Zhang Mingzhi M   Wu Jianqiu J   Liu Hui H   Zhang Pian P   Yang Su S   Zhou Zisong Z   Zheng Hongxia H   Song Yuqin Y   Zhu Jun J  

Cancer medicine 20201231 3


<h4>Background</h4>Despite numerous chimeric antigen receptor T-cell (CAR-T) trials conducted in China, no CAR-T has been registered in the country. Furthermore, China law and regulations restrict the export of patient material for CAR-T manufacture abroad. Relma-cel (JWCAR029), an anti-CD19 product produced with a commercial-ready process in China, was evaluated in the first prospective, single-arm, multicenter, pivotal study of CAR-T therapy conducted under Chinese IND to support an NMPA-accep  ...[more]

Similar Datasets

| S-EPMC4191682 | biostudies-literature
| S-EPMC7596761 | biostudies-literature
| S-EPMC8425084 | biostudies-literature
| S-EPMC7534065 | biostudies-literature
| S-EPMC6695562 | biostudies-literature
| S-EPMC9519531 | biostudies-literature
| S-EPMC10774422 | biostudies-literature
| S-EPMC8185372 | biostudies-literature
| S-EPMC8727291 | biostudies-literature
| S-EPMC8050776 | biostudies-literature